Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

ProMIS Neurosciences Inc PMN

ProMIS Neurosciences Inc. is a development stage biotechnology company. The Company is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA), an alpha-synucleinopathy. Its proprietary target discovery engine applies a thermodynamic, computational discovery platform - ProMIS and Collective Coordinates - to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product portfolio includes PMN310 / Amyloid-beta, PMN267 / TDP-43, and PMN442 / Alpha-synuclein. The Company plans to investigate additional synucleinopathies, including Parkinson's disease (PD) and dementia with Lewy bodies (DLB). Its wholly owned subsidiary is ProMIS Neurosciences (US) Inc.


NDAQ:PMN - Post by User

Bullboard Posts
Comment by retiredcopon May 16, 2018 5:01pm
72 Views
Post# 28042000

RE:RE:RE:RE:RE:Pathetic Performance

RE:RE:RE:RE:RE:Pathetic PerformanceI disagree .. Bob Gundel was lthe one eft with a leaking lifeboat ..by the way Bob G was recommended to Amorifx by George as a good succesor in the CEO position .. Bob tried to do too many things and as a result it failed and if you had a chance to talk to him he would admit that he had a huge task.and he felt like all he was doing was running from one hole to plug it and antoher one would spring open.. . but the positive thing in all of this was the stock went to the point where many of us couldnt help but load up on... now we reap the benefits ...  and the last thing is the deal with Biogen was a waste of time... they ended up doing sweet tweet and held up the ability for  Dr Cashman to continue doing work because George gave them exclusive rights with the opiton to renew .. which when it finally came around .. they didn't pursueand the science went bakc tio Dr Cashman .. It wasn' t till we got back the rights to the research and development,  was Dr Cashman able to go further and we can now see what it was capable of doing. These guys have a great corporate plan for the company and specfiic direction which you really diidnt see prior to 2015.        
Bullboard Posts